CouncilMonitor
194 principal councils 228,996 meetings since 2000 2.8 million official papers archived Straight from each council's own publication system
Oldham Metropolitan Borough Council
Council, Wednesday 20 March 2019 at 6.00pm

To note the Minutes of the following Partnership meetings and the relevant spokespersons to respond to questions from Members

Noted Committee 3 papers

Council noted this item on Wednesday 20 March 2019. Below is the council's own wording, with the papers it was decided on.

Item15b

Resolved

RESOLVED that the minutes of the Partnership meetings as detailed in the report be noted.
Word for word from the decision Oldham published for this meeting. Source: committees.oldham.gov.uk

Follow this further

Built from Oldham's papers

What the report saysPro

Report to Council

HEALTH AND WELL BEING BOARD 13/11/2018 at 2.00 pm

Present: Councillor Harrison (Chair) Councillors Chauhan, Jacques and Sykes

Also in Attendance: [name removed] Director, NHS Oldham Clinical Commissioning Group (CCG) Jill Beaumont Director of Children’s Health and Wellbeing, Oldham Cares Andrea Entwistle Principal Policy Officer Health and Wellbeing, OMBC Majid Hussain Lay Chair, Oldham CCG Superintendent Daniel Greater Manchester Police Inglis Merlin Joseph Interim Director of Children’s Services Stuart Lockwood Chief Executive, Oldham Community Leisure Donna McLaughlin Alliance Director, Oldham Cares Jason Rain Greater Manchester Fire and Rescue Services Katrina Stephens Joint Acting Director of Public Health / Consultant in Public Health, Health and Wellbeing, OMBC Rebekah Sutcliffe Strategic Director of Reform, OMBC Liz Windsor-Welsh Chief Executive, Acting Together Mark Warren Managing Director of Community, Health and Adult Social Care, OMBC Carolyn Wilkins Chief Executive, OMBC / Accountable Officer, Oldham Cares Fabiola Fuschi Constitutional Services Officer, OMBC

1 APOLOGIES FOR ABSENCE Apologies for absence were received from Councillor Chadderton, Julie Fairley, Nicola Firth, [name removed], Charlotte Stephenson, John Patterson and Julie Daines. 2 URGENT BUSINESS There were no items of urgent business received. 3 DECLARATIONS OF INTEREST There were no declarations of interest received. 4 PUBLIC QUESTION TIME The following public question was submitted by [name removed]: “To Health and Wellbeing Board, On the 17/10/18, I received an email from NHS England on ‘NHS set to save £150m by switching to a new version of most costly drug’

I would like to ask:

1) How many CCGs have started changing to the new drug? 2) When savings start to materialis(e), also on what time scale will it be before money from this to start re- investing, to benefit the patients and the care system, who this drug affects? 3) a. Is the £150m to be distributed across the whole of England? b. What will each area get in percentage, the whole amount or a share? 4) How will the re-investing money be used in Oldham?

For this report as a few good points to be looked in to, as we can get a(n) overall view from all perspectives.

Yours truly, James Allen

Cc Healthwatch Oldham, Cllr Jenny Harrison”

The following response was provided from the Health and Wellbeing Board:

We assume you are referring to NHS England guidance issued on 16 October concerning Adalimundab, a drug used for hospital treated, serious conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.

Previously Adalimumab has only been available under the brand name Humira. However, the patent on the drug has recently expired opening up the possibility of ‘biosimilar’ versions of Adalimumab being produced and prescribed in the NHS.

Adalimumab is the single medicine on which hospitals spend the most, at a cost of more than £400 million a year.

The guidance to Trusts and CCGs says that nine out of 10 new patients should be started on the best value medicine within three months of a biosimilar launch. At least 80% of existing patients should be switched to the best value biologic (which could be the originator or a biosimilar) within 12 months.

Biosimilar versions of Adalimumab are expected to be available to NHS patients from December this year, and could help save at least £150 million per year by 2021 depending on the price agreed for the drugs. The ongoing use of Humira may also continue where clinically appropriate and where it is best value.

To answer your questions: 1. How many CCGs have started changing to the new drug? None. No biosimilar versions of Adalimundab are available yet.

Read every report as text, not just the decision

Pro opens the officer report behind each decision, searchable and quotable, across every council we cover.

Papers for this item

Kept in our archive, download once signed in
PDF
2018.11.13 HWBB Minutes FinalMinutes 395 KB DownloadRead as text
PDF
MioCare Group Board Minutes Public 12th November 2018 KDMinutes 236 KB Download
PDF
To note the Minutes of the following Partnership meetings and the relevant spokespersons to respond to questions from MembersMinutes 127 KB Download

At this meeting

Whole meeting

Who was there

56 of 61 attended
RA
Riaz AhmadCommittee Member, present
SA
Shoab AkhtarCommittee Member, present
AA
Adrian AlexanderCommittee Member, present
GA
Ginny AlexanderCommittee Member, present
MA
Mohon AliCommittee Member, present
MA
Montaz Ali AzadCommittee Member, present
CB
Cath BallCommittee Member, present
MB
Marie BashforthCommittee Member, present
SB
Steven BashforthCommittee Member, present
NB
Norman BriggsCommittee Member, present
BB
Barbara BrownridgeCommittee Member, present
PB
Pam ByrneCommittee Member, present

All 61 on the meeting page

On this subject at Oldham

Search all
  1. To note the Minutes of the following Partnership meetings and the relevant spokespersons to respond to questions from MembersThis decision
  2. To note the Minutes of the meetings of the Cabinet held on the undermentioned dates, including the attached list of urgent key decisions taken since the last meeting of the Council, and to receive any questions or observations on any itemsNoted
  3. To note the Minutes of the following Joint Authority meetings and the relevant spokespersons to respond to questions from MembersNoted
  4. To note the Minutes of the meetings of the Cabinet held on the undermentioned dates, including the attached list of urgent key decisions taken since the last meeting of the Council, and to receive any questions or observations on any itemsNoted
  5. To note the Minutes of the following Partnership meetings and the relevant spokespersons to respond to questions from MembersNoted
  6. To note the Minutes of the following Joint Authority meetings and the relevant spokespersons to respond to questions from MembersNoted

More from Oldham Council

All decisions
MeetingDecisionOutcome
16 Sep 2026 To deal with matters which the Mayor considers to be urgent businessRESOLVED : That the Agenda of the meeting be varied to allow for Items 12, 15 and 11 to be debated after Item 9 and b... Decided Open
16 Sep 2026 To receive and note petitions received relating to the business of the CouncilRESOLVED : That the Report be noted. Noted Open
16 Sep 2026 Notice of MotionsRESOLVED : That Council suspend Council Procedure Rules 2.1.3 J and K for dealing with Administration and Opposition ... Decided Open
16 Sep 2026 Local Government and Social Care Ombudsman: Annual Review of Complaints 2025/26That the Report be NOTED. Noted Open
16 Sep 2026 Treasury Management Outturn Report 2025/27That the Report be NOTED. Noted Open

We use a cookie to keep you signed in and run your free-paper allowance, and an optional one to count visits. You can accept all, or choose. Privacy & cookies